lecanemab

Biogen is abandoning its lackluster Alzheimer’s disease drug, Aduhelm. The Massachusetts-based company announced Wednesday that it is pulling the medication from the market following poor sales and controversy over its approval by the Food and Drug Administration in 2021. The company says it is only doing so to “reprioritize” its resources toward its other, less contentious Alzheimer’s treatments, such as Leqembi.Lisa Frankenstein's Crew on Casting the Right Stars Adulhelm was developed by Biogen in conjunction with the…

On Thursday, the Food and Drug Administration made a decision that’s likely to have a major impact on the landscape of Alzheimer’s disease research. The agency issued a full-throated traditional approval of the drug Leqembi, developed by the companies Eisai and Biogen. The drug is the first of its class to receive such approval and is intended to slow down the progression of the neurodegenerative disease.Will We See More of Uhura's Relationship with Spock? | io9 InterviewLeqembi is one of several antibody-based drugs that…

No drug with consistent statistical evidence from clinical trials had ever been found to slow the course of Alzheimer’s disease before the Food and Drug Administration gave its nod this month to lecanemab, which clears the brain of the toxic amyloid protein that has been a primary target for drug developers. Lecanemab, marketed as Leqembi by the companies Eisai and Biogen, is not a cure for Alzheimer’s. Its sometimes serious side effects, modest benefits and yearly price of $26,500 (not yet covered by Medicare) are more…

Image: Shutterstock (Shutterstock)The Food and Drug Administration on Friday granted the conditional approval of a new treatment for people with early Alzheimer’s disease: the antibody-based drug lecanemab, jointly developed by the pharmaceutical companies Biogen and Eisai. In a large trial, lecanemab appeared to slow down patients’ cognitive decline relative to those on placebo. But some experts and consumer advocates have questioned the drug’s safety and real-world value.Lecanemab works by targeting amyloid beta, a…

MRI image of brain showing area of Alzheimer patient.Getty ImagesThe Food and Drug Administration on Friday granted accelerated approval for the Alzheimer's drug lecanemab, developed by Biogen and the Japanese pharmaceutical company Eisai.The FDA's approval comes after clinical trial results published in November indicated that lecanemab slows cognitive decline somewhat in people with mild impairment due to Alzheimer's disease, but the treatment also carries risks of brain swelling and bleeding.The agency can accelerate…

A new Alzheimer’s medication appears to be on the verge of approval by the US Food and Drug Administration. But such a major milestone, given the present paucity of effective treatments, has been complicated by fresh revelations about the FDA’s prior controversial approval of an Alzheimer’s drug — and lingering concerns among some experts that the hype could once again get out ahead of the science. The federal agency is expected to make a decision by Friday about whether to grant accelerated approval to lecanemab, an…

Alzheimer’s Drug Discovery Foundation announced that the amyloid-clearing drug lecanemab will be a positive step in the treatment of Alzheimer’s disease based on study results presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference and published in The New England Journal of Medicine.Positive results from new amyloid-clearing drug represent a starting point for <span class="glossaryLink" aria-describedby="tt" data-cmtooltip="<div…

Image: Shutterstock (Shutterstock)An experimental treatment for Alzheimer’s disease may pose a life-threatening risk of brain bleeding for certain patients, an investigative report out this week suggests. The paper, published Monday in the journal Science, details the case of a 65-year-old woman who died from massive hemorrhaging that could have arisen from taking a common blood thinner while on the experimental drug. The incident is believed to be the second similar death linked to the treatment, which will be reviewed…

Biogen Inc. and partner Eisai Co. surged and led other…